HOSPITAL UNIVERSITARIO RUBER
Departamento
Hospital Universitario Arnau de Vilanova
Lleida, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Arnau de Vilanova (12)
2021
-
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Breast Cancer Research, Vol. 23, Núm. 1
-
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
npj Precision Oncology, Vol. 5, Núm. 1
-
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients
Cancer Treatment Reviews, Vol. 83
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Journal of the National Cancer Institute, Vol. 112, Núm. 1, pp. 46-54
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Breast Cancer Research, Vol. 22, Núm. 1
-
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial
Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Nature Communications, Vol. 11, Núm. 1
-
Randomized phase 0/I trial of the mitochondrial inhibitor Me-344 or placebo added to bevacizumab in early HER2-negative breast cancer
Clinical Cancer Research, Vol. 26, Núm. 1, pp. 35-45
2018
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
-
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 4, pp. 545-554